October 8, 4pm-5:30pm: NAMI’s Ask the Expert Webinar: New Horizons in Schizophrenia Research
This webinar will review the latest developments in NIMH-sponsored research including the recently announced Accelerating Medicines Partnership (AMP) Schizophrenia, a public-private partnership to advance the understanding of the risk factors for developing schizophrenia and promising new avenues for treatment.
A number of novel treatment strategies for schizophrenia have shown promise, but changes in response have been a major challenge. One way to address this challenge is to identify biomarkers that may predict the course of the illness and assist in the design of clinical trials of new medications that can address the variability in treatment response.
Dr. Lisanby will review exciting developments underway related to large-scale studies focused on identifying biomarkers related to schizophrenia, with the long-term goal of leading to development of effective treatments and prevention strategies individualized for the needs of each person.
At the end of this presentation, NAMI’s Chief Medical Officer, Dr. Ken Duckworth, will moderate a question and answer session with Dr. Lisanby.
Sarah Hollingsworth “Holly” Lisanby, MD, is the Director of the Division of Translational Research at the National Institute of Mental Health (NIMH) which funds research supporting the discovery of preventions, treatments, and cures for mental illness across the lifespan. Dr. Lisanby is well known for her pioneering research leading to the FDA approval of novel devices for the treatment of depression (including Transcranial Magnetic Stimulation (TMS) and vagus nerve stimulation (VNS) and on novel devices in development (including Magnetic Seizure Therapy). She is an internationally renowned physician, psychiatrist, researcher, leader, and innovator of neuromodulation technologies to study and treat psychiatric disorders. She was the first woman to become Chair of the Department of Psychiatry of Duke University. A prolific author with over 280 scientific publications, she has received national and international recognition for her innovations in the treatment of schizophrenia and depression.
This webinar will be recorded.
Questions? Contact us at email@example.com